Regeneration Technologies, Inc. (RTI) is engaged in the production of allografts that repair and promote the natural healing of human bone and other human tissues. The Company processes human musculoskeletal and other tissue, including bone, cartilage, tendon, ligament, dermal and cardiovascular tissue in producing its allograft implants. These allografts are distributed throughout the United States and in 10 countries, for use in spinal vertebrae repair, musculoskeletal reconstruction, fracture repair, repairs to the jaw and related tissues, and heart valve disorders, among other conditions. The Company separates its allografts into four primary product lines: spinal, sports medicine, cardiovascular and other general orthopedic applications. These allografts range from material that is precision tooled for specific surgical applications to grafts conventionally processed for general surgical uses.